83799-24-0
83799-24-0 structure
- Name: Fexofenadine
- Chemical Name: fexofenadine
- CAS Number: 83799-24-0
- Molecular Formula: C32H39NO4
- Molecular Weight: 501.656
- Catalog: API Antiallergic Antihistamine
- Create Date: 2018-07-16 19:41:12
- Modify Date: 2024-01-02 17:25:13
-
Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].
| Name | fexofenadine |
|---|---|
| Synonyms |
4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-α,α-dimethylbenzeneacetic acid
Fexofenadine-D5 Fexafenadine 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)phenyl)-2-methylpropionic acid CARBOXYTERFENADINE Fexofenadine benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-a,a-dimethyl- Terfenadine acid TERFENADINECARBOXYLATE Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- Telfast MFCD00871892 2-[4-(1-Hydroxy-4-{4-[hydroxy(diphenyl)methyl]-1-piperidinyl}butyl)phenyl]-2-methylpropanoic acid 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid Fexofenadinebase |
| Description | Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
H1 Receptor |
| In Vitro | Fexofenadine (1-100 µM; 1 h) inhibits the expression of IL-6 protein in nasal fibroblasts in a dose-dependent manner[2]. Fexofenadine (1-100 µM; 1 h) blocks phosphorylated p38 activation in histamine-induced nasal fibroblasts, but shows no effect on either pERK or pJNK[2]. Western Blot Analysis[2] Cell Line: Nasal fibroblasts Concentration: 100 μM Incubation Time: 1 hour Result: Blocked pp38 activation in histamine-induced nasal fibroblasts, showed histamine-induced IL-6 production mediated by the p38 pathway. |
| In Vivo | Fexofenadine hydrochloride (oral administration; 5-20 mg/kg; once daily; 3 w) suppresses both eosinophilia and systemic anaphylaxis in C57BL/6 mice infected with T. spiralis[1]. Animal Model: C57BL/6 mice infected with Trichinella spiralis[1] Dosage: 5, 10 and 20 mg/kg Administration: Oral administration; 5, 10 and 20 mg/kg; once daily; 3 weeks Result: Inhibited eosinophilia in a dose-dependent manner. Suppressed the decrease in rectal temperature (p<0.01), a marker for systemic anaphylaxis. |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 697.3±55.0 °C at 760 mmHg |
| Melting Point | 218-220ºC |
| Molecular Formula | C32H39NO4 |
| Molecular Weight | 501.656 |
| Flash Point | 375.5±31.5 °C |
| Exact Mass | 501.287903 |
| PSA | 81.00000 |
| LogP | 4.80 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.597 |
| Storage condition | -20°C Freezer |
| HS Code | 2933399090 |
|---|
| Precursor 6 | |
|---|---|
| DownStream 1 | |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |